A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS
Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
This is a two strata Phase 1b study to assess the safety and efficacy of bisantrene (RC110)
in combination with a) cytarabine arabinoside (Ara-C) treatment for patients with relapsed or
refractory (R/R) Acute Myeloid Leukemia (AML) with extramedullary disease and able to
tolerate intensive chemotherapy; b) in combination with decitabine/cedazuridune (ASTX727) new
or relapsed or refractory AML or high risk MDS or CMML with extramedullary disease and unable
or not willing to have intensive chemotherapy.